Traws Pharma, Inc. Common Stock (TRAW) — Analysis Summary
Traws Pharma, Inc. Common Stock (TRAW) has a market cap of $6.84M with year-over-year revenue growth of +1134.5%. Net margin stands at 328.7%. The stock trades at a P/E ratio of -0.3.
Key Takeaways
- Revenue changed +1134.5% year-over-year
- Net margin of 328.7%
- P/E ratio of -0.3
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, TRAW posted revenue growth of +1134.5% and trades at a P/E of -0.3.
Traws Pharma, Inc. Common Stock (TRAW)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -772.2% — severe operating losses
Net margin at -773.0% — losses exceed revenue (possible one-time charges)
Net income turned negative after a profitable prior period.
Current ratio at 0.93x — current liabilities exceed current assets
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
7
Headquarters
NEWTOWN, PA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.